CD1D and myeloid leukemia: In myeloid leukemia patients, for instance, purified PBMCs-derived iNKT cells are responsive to stimulation with α-GalCer/CD1d-tetramer with production of IFN-γ, TNF-α, IL-2, and IL-4 and cytotoxic against autologous leukemic cells, that are CD1d+ (Metelitsa et al., 2003).